Tom Barnes, Orna Therapeutics CEO

'We have failed to fail': Mer­ck gam­bles $250M cash on a next-gen ap­proach to mR­NA — af­ter punt­ing its big al­liance with Mod­er­na

Mer­ck went in deep on its col­lab­o­ra­tion with Mod­er­na on new mR­NA pro­grams, and dropped them all over time, in­clud­ing their RSV part­ner­ship. But af­ter writ­ing off what turned out as one of the most suc­cess­ful in­fec­tious dis­ease play­ers in the busi­ness, Mer­ck is com­ing in this morn­ing with a new pre­clin­i­cal al­liance — this time em­brac­ing a biotech that hopes to even­tu­al­ly out­do the fa­mous­ly suc­cess­ful mR­NA in a new run at vac­cines and ther­a­peu­tics.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.